格陵蘭礦業公司舉辦採礦與生物技術項目簡報會
Greenland Mines Hosts Briefing on Mining and Biotech Projects
在一場大膽的戰略轉型中，Klotho Neurosciences正式更名為Greenland Mines Ltd（納斯達克代碼：GRML）。
In a bold strategic shift, Klotho Neurosciences has officially rebranded as Greenland Mines Ltd (Nasdaq: GRML).
該公司總部位於北卡羅來納州夏洛特市，採用了獨特的雙重商業模式，將高科技基因療法與北極自然資源探勘相結合。
Based in Charlotte, North Carolina, the company has adopted a unique dual-business model that combines high-tech gene therapy with Arctic natural resource exploration.
在繼續推進其針對肌萎縮性脊髓側索硬化症（ALS）的KLTO-202候選療法之同時，該公司正積極開展位於格陵蘭島東南部的Skaergaard計畫。
While continuing to advance its KLTO-202 therapy candidate for Amyotrophic Lateral Sclerosis (ALS), the company is aggressively pursuing the Skaergaard Project in southeast Greenland.
此礦業合資企業持股比例為80%，目標為全球最大的未開發鈀、金、鉑礦床之一。
This mining venture, which holds an 80% interest, targets one of the world's largest undeveloped deposits of palladium, gold, and platinum.
為確保符合環保規範，公司正在進行多年期的生物調查，並已加入格陵蘭商業協會以促進當地經濟聯繫。
To ensure environmental compliance, the company is conducting multi-year biological surveys and has joined the Greenland Business Association to foster local economic ties.
儘管潛力巨大，該公司仍面臨重大阻礙，包括納斯達克關於最低投標價格的合規性挑戰。
Despite this massive potential, the company faces significant hurdles, including Nasdaq compliance challenges regarding its minimum bid price.
